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Immune cells are, by default, migratory cells that traverse tissue for the purpose
of carrying out recognition and recruitment in pathologic inflammation and infection.
Members of the LDL receptor family (LDL-RFMs) interact with human leukocyte elastase
on the cell surface (HLE-CS) in complex with the abundant blood protein α1proteinase
inhibitor (α1PI, α1-antitrypsin, Alpha-1), a process that induces internalization of
aggregated functionally-related receptors, including CD4 and the T cell antigen receptor,
while simultaneously promoting cellular locomotion. We sought to determine whether
augmenting α1PI blood concentration would promote the locomotion of immature T
cells through the thymus and generate new CD4+ T cells. Two small clinical trials
(NCT01370018, NCT01731691, https://clinicaltrials.gov) were conducted in which HIV-1
infected and uninfected individuals were augmented with α1PI and compared with
placebo-treated subjects and untreated controls. Blood cell phenotypes were monitored
weekly. We found that CD4/CD8 ratio was significantly increased by α1PI augmentation in
both uninfected and HIV-1 infected individuals. We found that maturation of CD4+CD8+
T cells to become immunologically competent CD4+ T cells was regulated by α1PI. We
propose a strategy targeting HLE-CS for treating secondary immunodeficiency for which
there is currently no direct treatment. Treatment to directly elevate T cells in patients
with secondary immunodeficiency, including HIV disease, can be provided by alpha-1
antitrypsin augmentation or small molecules that target HLE-CS. Because individuals
infected with HIV-1 produce a monoclonal antibody, 3F5, which binds to and inactivates
α1PI, a process that prevents α1PI from binding to HLE-CS, thereby blocking locomotion
of immature T cells through the thymus to generate CD4+ T cells, we further propose that
HIV-1 vaccination should include induction of an antibody that binds to and blocks 3F5
activity, thereby preventing AIDS in addition to the current vaccine strategy for preventing
HIV-1 infection.
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INTRODUCTION
There are many receptor-proteinase inhibitor pairs that induce
cellular locomotion, one of which involves the protein encoded
by SERPINA1 (α1proteinase inhibitor, α1PI, α1antitrypsin, AAT,
Alpha-1) which is normally found at much greater concentration
than any other proteinase inhibitor. A primary physiological
role for α1PI is to induce cellular locomotion through tissue by
binding to human leukocyte elastase on the cell surface (HLE-
CS). When LDL receptor family members (LDL-RFMs) on the
cell surface form a complex with α1PI and HLE-CS, endocytosis
is induced, which results in internalization of adhesion molecules
at the trailing edge of a migrating cell thereby propelling a cell
forward as it traverses tissue (Schmitz et al., 2003; Bristow et al.,
2013). In physiological conditions, subsequent to endocytosis,
recycling receptors that are aggregated with LDL-RFMs are
returned to the cell surface in early endosomes for reuse. In
pathological conditions, α1PI is inactivated by proteinases other
than elastase and immune cell locomotion halts precisely at the
site of infection or inflammation. This mechanism includes the
locomotion of progenitor cells through thymic tissue and the
generation of new CD4+ T cells in mice and humans (Spurll and
Owen, 1981; Owen and Riblet, 1984; Bristow and Flood, 1993). In
the absence of sufficient functional α1PI, immature T cells poorly
migrate through the thymus to generate new CD4+ T cells.
Generation of new CD4+ T helper cells from progenitor
cells occurs in known discrete steps (Figure 1). When CD34+
hematopoietic progenitor cells are released from bone marrow
and during the process of traversing tissue, they mature to
become CD25+ pre-T cells which do not express CD4 or CD8
on the cell surface, accordingly termed double negatives (DNs).
These DNs also do not express the T cell antigen receptor (TcR)
or its coreceptor CD3 on the cell surface. After arriving in the
thymus, DNs mature through four distinct stages to express
both CD4 and CD8 on the cell surface, termed double positives
(DPs). In the process of maturing from DNs to DPs, the TcR
β-chain rearranges forming cytoplasmic DNA fragments termed
β-chain T cell excision circles (β-TRECs). Subsequently, the TcR
α-chain rearranges to form signal joint TRECs (sj-TRECs). Once
these TcR chains are assembled intracellularly, the intact TcR is
expressed on the cell surface in tandem with CD3. Due to this
process, the sj/β-TREC ratio has been shown to be useful for
quantitating the maturation of DNs to DPs (Ferrando-Martínez
et al., 2010). DPs mature to become single positive T cells (SPs)
that express either CD4 or CD8 on the cell surface. These SPs
undergo positive and negative selection within the thymus via
antigen recognition avidity and are released into blood and tissue
where they generally act as effector helper T cells or killer T cells,
respectively. Total thymic output is relatively invariable in an
individual, and by default, DPs mature to become CD8+ T cells.
Abbreviations: α1PI, α1proteinase inhibitor, α1antitrypsin, Alpha-1; bNAbs,
broadly neutralizing antibodies; HLE-CS, human leukocyte elastase on the cell
surface; LDL-RFM, LDL receptor family members; TRECs, T cell receptor excision
circles; DN, double negative CD4−CD8− T cells; DP, double positive CD4+CD8+
T cells, SP, single positive CD4+ or CD8+ T cells.
FIGURE 1 | Influence of α1PI on thymopoiesis. By default, DP T cells mature
to become CD8+ SP T cells. Signaling induced by binding of α1PI to HLE-CS
on DP T cells induces NFκB phosphorylation and stimulates the maturation of
DP T cells to become CD4+ SP T cells.
However, when DPs do not mature to CD8+ T cells, they become
CD4+ T cells (McDonagh and Bell, 1995).
Clinically, α1PI deficiency (genetic or acquired) is an
underlying condition in chronic obstructive pulmonary disease
(COPD), a common symptom of HIV-1 disease consistent with
disease attendant acquired α1PI deficiency (Bristow et al., 2001).
Interestingly, patients with genetic α1PI deficiency have relatively
normal numbers of CD4+ T cells (Bristow et al., 2012). This is
thought to be due to the normal production and secretion of α1PI
by cells within lymphoid tissues where α1PI protein synthesis is
initiated using different promoters in contrast to those used by
liver cells where secretion is severely inhibited (Gullberg et al.,
1997; OMIM, 2019). This concept is supported by the presence
of detectable α1PI (2–5µM) in genetically deficient patients,
representing 10% of the normal reference range (18–53µM)
(Bristow et al., 2001). An alternative explanation is that similar
receptor-proteinase inhibitor pairs (or receptor-proteinase pairs)
could substitute for the funtions of the α1PI-HLE pairs.
While COPD often manifests in HIV-1 disease, the principal
pathology is loss of CD4+ T cells, and this has been attributed to
both increased CD4+ T cell death and decreased generation of
new CD4+ T cells (Ribeiro et al., 2002; Dion et al., 2006; Bristow
et al., 2010, 2013). The failure of CD4+ T cell renewal in HIV-1
infected individuals has been linked to acquired α1PI deficiency
which is caused by onemonoclonal antibody, 3F5, with specificity
for HIV-1 envelope protein gp120 (Bristow et al., 2010, 2012).
Current approaches to HIV-1 vaccine development are to
induce broadly neutralizing antibodies (bNAbs) to block direct
fusion of the virus to a cell’s plasma membrane. However,
microscopic imaging has indisputably demonstrated HIV-1
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fusing with the plasma membrane within endosomal vesicles, a
process that sequesters virions from bNAbs (Hubner et al., 2009;
Miyauchi et al., 2009; Bristow et al., 2013; Herold et al., 2014;
Law et al., 2016). CD4-coupled HIV-1 has been demonstrated to
be internalized via endocytosis mediated by LDL-RFMs (Bristow
et al., 2003, 2013).
Many bNABs (e.g., 2F5 and 4E10) additionally bind to human
proteins and may also induce autoimmunity. The possibility of
such autoimmunity has been largely dismissed as too daunting
to consider and an improbable outcome in HIV-1 vaccine design
(Haynes et al., 2005). However, 3F5 (same epitope recognition
as 1C1), has specificity for HIV-1 envelope protein gp120
and produces autoimmunity in humans (Los Alamos National
Laboratory, 2009; Bristow et al., 2012). In the absence of viral
particles, 3F5 binds to and inactivates human α1PI, an abundant
blood protein (Uhlen et al., 2010; Uhlén et al., 2015; Bristow
et al., 2012). In the early stages of HIV-1 disease, 90% of HIV-
1 patients have detectable 3F5-induced α1PI deficiency (Bristow
et al., 2001). Thus, α1PI is an inadvertant autoimmune target of
the HIV-1 antibody response.
We proposed that 3F5-mediated inactivation of α1PI impedes
endocytosis thereby thwarting the movement of cells through
the thymus and blocking generation of CD4+ T cells (Bristow
et al., 2012). This hypothesis suggests that α1PI augmentation
therapy might increase the number of CD4+ T cells in blood.
We demonstrate herein that α1PI augmentation increases the
number of CD4+ T cells in blood by increasing the percentage
of DPs that mature to become CD4+ T cells during thymopoiesis
via a mechansim involving CD3+HLE+ thymocytes.
MATERIALS AND METHODS
Clinical Trial NCT01370018
This clinical trial had one treatment arm. Using the empirical
correlation between α1PI and CD4+ lymphocytes, a sample
size of 2 HIV-1 infected subjects were adequate to determine
treatment efficacy with a significance level with alpha= 0.05 and
power of test= 0.8. Written informed consent was received from
4 male HIV-1 subjects (Table 1). Inclusion criteria for treatment
were: (i) active α1PI below 11µM; (ii) 1 year history with CD4+
lymphocytes at levels ranging between 150 and 300 cells/µl; (iii)
absence of symptoms suggestive of HIV-1 disease progression;
(iv) adequate suppression of virus (<50 HIV RNA/ml); and (v)
history of compliance with antiretroviral medication. Due to the
small size of the pilot study and to avoid other complications
of pregnancy, only male HIV-1 infected subjects were enrolled.
CSL Behring contributed a sufficient quantity of Zemaira R© (lot#
C405702) for administration of 8 weekly infusions at a dose of
120 mg/kg. Zemaira (α1PI that is purified from plasma) has a
half-life after infusion of 4.5 days reaching steady state after 3–4
weeks therapy (Bayer, 2003).
For comparison, we included 2 HIV-1 uninfected patients,
both female, with a diagnosis of COPD in the context of genetic
α1PI deficiency (PIzz) who were initiating clinical treatment
using Prolastin at a dose of 60 mg/kg. Both subjects provided
written informed consent.
Each subject was infused at the same time of day and same
day of week throughout the study. Blood was collected weekly
pre-infusion to monitor changes.
TABLE 1 | Enrolled population characteristics at baseline.
Clinical trial Subject category Age range Active α1PI (µM) CD4 (cells/µl) HIV RNA
(copies/ml)
Treatment Arm
NCT01370018
Pizz-1 50–55 5 743 NA Prolastin (60 mg/kg)
Pizz-2 50–55 4 899 NA Prolastin (60 mg/kg)
HIV subject-1 46–50 9 297 <400 Zemaira (120 mg/kg)
HIV subject-2 50–55 7 276 <400 Zemaira (120 mg/kg)
HIV subject-3 66–70 4 148 <400 Zemaira (120 mg/kg)
HIV subject-4 50–55 14 445 205 Zemaira (120 mg/kg)
NCT01731691
uninfected-1 20–25 28 426 NA Untreated
uninfected-2 40–45 31 583 NA Untreated
uninfected-3 26–30 9 604 NA Untreated
uninfected-4 36–40 15 989 NA Untreated
HIV subject-1 56–60 11 280 <40 Prolastin-C (120 mg/kg)
HIV subject-2 46–50 13 318 <40 Prolastin-C (120 mg/kg)
HIV subject-3 56–60 18 497 <40 Prolastin-C (120 mg/kg)
HIV subject-4 50–55 9 274 <40 Placebo
HIV subject-5 46–50 12 501 <40 Placebo
HIV subject-6 40–45 4 382 <40 Placebo
HIV subject-7 50–55 16 522 <40 Placebo
HIV subject-8 56–60 18 510 <40 Placebo
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One HIV-1 infected subject who was PPD positive
(tuberculosis skin test) had become PPD negative 2 years
prior to Zemaira treatment which is clinically interpreted as a
loss of immune function. One HIV-1 infected subject reported to
the first infusion stating that due to unforeseen circumstances, his
antiretroviral medication was interrupted for 4 days. Although
there was no fever present or other indication of infection at
the time of the first infusion, in follow-up analyses, this subject
was found to have pre-treatment serum IL-2 levels of 51 pg/ml
(normal is undetectable) and other atypical baseline measures
indicative of an inflammatory response which exceeded study
inclusion criteria including 454 CD4+ cells/µl, 205 HIV RNA
copies/ml, and 14µM α1PI. Thus, blood from this subject was
analyzed for the purpose of assessing treatment response in the
presence of systemic inflammation.
To determine immunocompetence, CD4+ T cells isolated
from blood samples acquired pre- and post-Zemaira treatment
were analyzed for NFκB activation, cytokine release, and
lymphocyte phenotype.
Blood collected at each session was sent to a contractor
medical laboratory which provided independent measurement of
the complete blood cell count (CBC) with differential, lipid panel,
blood chemistry, lymphocyte panel, and HIV RNA. Periodically,
kidney (BUN and creatinine) and liver function tests (ALT, AST)
were monitored for potential immune complex disease, and all
measurements were found to be within the normal range. The
study protocol was approved by the Institutional Review Board of
Cabrini Medical Center, New York, NY. No adverse effects were
reported by any volunteers, and all volunteers remained in the
study for the full period with the exception of one HIV-1 subject
who agreed to stay in the study for an extra 4 weeks and one PIzz
clinic patient who withdrew after the fifth week of the study due
to disease-related weakness.
Clinical Trial NCT01731691
This clinical trial was a double-blind, randomized study. Written
informed consent was received from 12 subjects, 8 HIV-1 infected
subjects and 4 uninfected controls (Table 1). Inclusion criteria for
HIV-1 infected subjects were the same as NCT01370018 with the
exception that viral load<1,000HIVRNA/ml was allowable. Due
to a lack of successful accrual, inclusion criteria were modified
to allow individuals with 1 year history of CD4+ lymphocytes
at levels ranging between 200 and 600 cells/µl. Randomization
(roll of dice) resulted in 5 HIV-1 infected subjects assigned to
placebo treatment and 3 HIV-1 infected subjects assigned to α1PI
treatment. HIV uninfected, untreated controls were monitored
weekly, and inclusion criteria were the same as for HIV-1 infected
subjects excluding HIV-related criteria. All female subjects were
required to use contraceptives and were monitored weekly for
HCG levels to detect potential pregnancy. Grifols Biotherapeutics
contributed a sufficient quantity of Prolastin-C (lot# 26NLK52)
for administration of 8 weekly infusions at a dose of 120 mg/kg.
Prolastin-C (α1PI that is purified from plasma) is equivalent in
activity to Zemaira.
The study protocol was the same as for NCT01370018 and
was approved by Copernicus Group Independent Institutional
Review Board, Durham, NC. Drug delivery and blood collection
were performed at ACRIA, New York, NY. No adverse effects
were reported by any volunteers, and all volunteers remained in
the study for the full period.
Serum α1PI Levels
Active and inactive α1PI levels were determined in once-thawed
serum samples as previously described (Bristow et al., 1998).
Active α1PI represents that fraction of total α1PI that binds to
elastase and the residual represents inactive α1PI. Total α1PI
levels, measured by ELISA, were confirmed by GeneAidyx,
Alachua, FL.
Lymphocyte Extended Phenotype Analysis
Surface staining on whole blood was performed as previously
described (Bristow et al., 2010). Fluorescently conjugated ASR
monoclonal antibodies and isotype controls (BD Biosciences)
were used to quantitate CD3, CD4, CD8, CD45RA, CD45RO,
CXCR4, CCR5, CD34, CD25. Cells were subsequently stained
to detect HLE-CS by incubating whole blood for an additional
15min at 23◦Cwith rabbit anti-HLE (Biodesign, Kennebunkport,
ME) or negative control rabbit IgG (Chemicon, Temecula, CA)
each of which had been conjugated to Alexa Fluor 647 (Molecular
Probes). At least 10,000 cells from each sample were acquired.
Markers on cells in the lymphocyte gate were quantitated. In
clinical trial NCT01370018, flow cytometry was performed by the
investigators. In clinical trial NCT01731691, flow cytometry was
performed by a contractor medical laboratory.
CD4+ Lymphocyte Functional Analysis
CD4+ lymphocytes were negatively selected from peripheral
blood mononuclear cells (PBMC) using magnetic cell sorting as
recommended by the manufacturer (Miltenyi Biotec, Auburn,
CA). Isolated cells (1 × 106 cells/ml) were cultured in
medium containing 10% FBS in 24-well tissue culture plates
for 3 days at 37◦C, 5% CO2, in the presence or absence of
stimulation antibodies reactive with CD2, CD3, and CD28 as
recommended by the manufacturer (Miltenyi Biotec). Culture
supernatants were measured by ELISA as recommended by the
manufacturer (R&D Systems, Minneapolis, MN) for IL-2, IL-4,
IL-10, and IFNγ.
Harvested CD4+ lymphocytes were examined for NFκB
phospho-epitope staining by flow cytometry as previously
described using phosphoprotein-specific antibodies (BD
Pharmingen and BD PhosFlow, San Diego, CA) directly
conjugated with Alexa Fluor 647 (Molecular Probes Invitrogen,
Carlsbad, CA) (Krutzik and Nolan, 2006).
sj/β-TREC Ratio Quantification
Thymic function was indirectly calculated in peripheral PBMC
DNA using the sj/β-TREC ratio previously described with minor
modifications (Ferrando-Martínez et al., 2010). Briefly, the six
DβJβ-TRECs from cluster one were amplified together in the
same PCR tube, whereas the sj TREC was amplified in a different
PCR tube. Twenty-one amplification rounds were performed
to guarantee an accurate quantification at the real-time PCR
step. All amplicons (DβJβ- and sj-TRECs) were then amplified
together in a second PCR using a LightCycler 480 system
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(Roche). Six µL of a 1/10 dilution of the first-round PCR were
amplified in a 20 µL final volume. Forster resonance energy
transfer (FRET) specific probes were used for specific detection.
Statistical Analysis
Correlation and % change from baseline statistical analyses
were performed using all available data points in all treatment
arms including untreated controls. Most parameters were not
normally distributed. Correlation coefficients were determined
by Spearman Rank Order unless stated otherwise. Comparison
of median values were performed using Mann-Whitney Rank
Sum Test.
RESULTS
Influence of α1PI Therapy on CD4+ T Cell
Numbers
The number of CD4+ T cells and CD4/CD8 ratio were
significantly increased following clinical initiation of weekly
Prolastin therapy in patients with genetic α1PI deficiency (PIzz,
n = 2, P = 0.01, and P < 0.04) (Figures 2A,B) (Bristow et al.,
2010). Subjects infected with HIV-1 were enrolled in clinical
trials to examine the capacity of weekly α1PI to elevate CD4+ T
cells (Bristow et al., 2010). Following 2 weeks of weekly Zemaira
therapy, below normal CD4 counts significantly increased to
normal levels of immunocompetent CD4+ T cells in 2 subjects
(P < 0.001 and P < 0.05) with no adverse effects (Figure 2A).
One HIV-1 subject (HIV subject-3) who had lost the capacity
to respond to antigenic challenge (positive PPD followed by
negative PPD) showed no increase in CD4+ T cells. CD4/CD8
ratio % change from baseline was significantly elevated following
Zemaira treatment as well as following Prolastin-C treatment as
compared to placebo (Figure 2B).
Influence of α1PI Therapy on Thymopoiesis
To investigate whether α1PI therapy influences the generation
of new CD4+ T cells in the thymus, markers of thymopoiesis
were measured weekly using peripheral blood from uninfected,
untreated subjects and from Prolastin-C-treated and placebo-
treated HIV-1 infected subjects. Markers included CD34+ cells
(pre-thymic progenitor cells), sj/β-TRECs (quantitation of DN to
DP maturation), and DPs (pre-SP cells).
The % change from baseline in CD4 counts was not
significantly improved in Prolastin-C-treated subjects (Table 2,
columns 2, 3, row 2), but increased CD4 counts had been
observed with Zemaira and Prolastin treatment (Table 2,
columns 4, 5, row 2). In Prolastin-C treatment, CD4%
significantly improved relative to placebo treatment (P <
0.01, Table 2, columns 2, 3, row 1) as was also observed in
Zemaira treatment (Table 2, column 4, row 1. In addition, CD8
counts (P < 0.05, Table 2, columns 2, 3, row 4) and CD8%
(P < 0.001, Table 2, columns 2, 3, row 3) were significantly
decreased in Prolastin-C treated subjects as compared to placebo-
treated subjects thereby resulting in CD4/CD8 ratios that
were significantly higher in Prolastin-C-treated subjects than in
placebo-treated subjects (P = 0.002, Table 2, columns 2, 3, row
5, Figure 2B) as was also observed with Zemaira and Prolastin
FIGURE 2 | Increased CD4+ T cells in α1PI-treated subjects. (A) Two
Prolastin-treated patients genetically deficient for α1PI (PIzz, black bars)
exhibited significantly elevated CD4+ T cells (P < 0.01 and P < 0.04) as
compared to four untreated controls (gray bar). Zemaira-treated HIV subject-1
(P < 0.001) and HIV subject-2 (P < 0.05) (green bars) exhibited significantly
elevated CD4+ T cells as compared to the four uninfected, untreated controls.
HIV subject-3 had lost T lymphocyte-mediated immune response and showed
no change in CD4+ T cells following Zemaira treatment. (B) Two Prolastin-
treated PIzz patients exhibited significantly elevated CD4/CD8 ratio (P < 0.04,
black bars) as compared to four uninfected, untreated controls (gray bar). HIV
infected subjects (green bars) exhibited CD4/CD8 ratios that were significantly
elevated following treatment with Zemaira (P < 0.001, excluding subject-3)
and with Prolastin-C (P = 0.002) as compared to five subjects treated with
placebo. Mean % change from baseline and standard deviations are depicted
where % change = 100 × [(Treatment week-Baseline)/Baseline]. Askerisks
designate statistically signifant difference (*P < 0.05, **P < 0.01, ***P <
0.001). Data represent nine measurements per subject and were not normally
distributed. Comparisons were performed using Mann-Whitney Rank
Sum test.
treatment (Table 2, columns 4, 5, row 5). CD34+ progenitor
cells were increased in placebo-treated subjects and to a lesser
extent in Prolastin-C treatment (P < 0.07, Table 2, columns 2,
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3, row 9) although the difference did not reach significance. The
relative decrease in % change from baseline in CD34+ progenitor
cells in Prolastin-C-treated subjects vs. placebo-treated subjects
is important to note because the % change from baseline in PIzz
Prolastin-treated clinic patients dramatically increased (Table 2,
column 5, row 9).
In addition to change from baseline, relationships between
markers of thymopoiesis and cell phenotypes were altered by
Prolastin-C treatment as follows:
CD4/CD8 Ratio (Table 3 Part 1, Column 1)
In uninfected controls, as expected, increased CD4/CD8 ratio
correlated with increased absolute CD4+ T cells and with
increased DPs. In HIV-1 infected subjects, Prolastin-C treatment,
but not placebo treatment, corrected the relationship between
the CD4/CD8 ratio and absolute CD4+ T cells as well as the
relationship between CD4/CD8 ratio and DPs to resemble that
of uninfected controls (Table 3 Part 1, column 1, rows 2 and 8).
In uninfected controls, CD4/CD8 ratio was not correlated
with absolute CD8+ T cells, but in placebo treatment and
Prolastin-C treatment increased CD4/CD8 ratio was correlated
with decreased absolute CD8+ T cells (Table 3 Part 1, column
1, row 4). Further, in uninfected controls, increased CD4/CD8
ratio was correlated with increased absolute CD3+ T cells, but
in placebo treatment and Prolastin-C treatment, CD4/CD8 ratio
was correlated with decreased absolute CD3+ T cells (Table 3
Part 1, column 1, rows 6 and 7). These results suggest that
Prolastin-C treatment caused an increase in CD4/CD8 ratio by
increasing DPs and CD4+ T cells, not by decreasing absolute
CD3+ or CD8+ T cells.
CD34+ Progenitor Cells (Table 3 Part 1,
Column 2)
In uninfected controls, increased CD34+ progenitor cells (%
lymphocyte gate) were correlated with increased absolute CD4+
T cells, increased absolute CD3+ T cells, and increased absolute
CD8+ T cells (Table 3 Part 1, column 2, rows 2, 4, 7). In
contrast, in placebo treatment, increased CD34% was correlated
with decreased absolute CD4+ T cells, decreased absolute CD3+
T cells, and decreased absolute CD8+ T cells (Table 3 Part 1,
column 2, rows 2, 4, 7).
In Prolastin-C-treated subjects, there was no correlation
between CD34% and absolute CD3+ T cells or absolute CD8+
T cells, but increased CD34% was correlated with decreased
absolute CD4+ T cells (Table 3 Part 1, column 2, rows
2, 4, 7). Further, in uninfected controls, CD34% was not
correlated with DPs. In placebo treatment, increased CD34% was
correlated with increased DPs, whereas in Prolastin-C treatment,
increased CD34% was correlated with decreased DPs (Table 3
Part 1, column 2, row 8). While Prolastin-C treatment did
not significantly increase or decrease CD34+ progenitor cells
(Table 2, columns 2, 3, row 9), these correlation comparisons
suggest that Prolastin-C treatment altered the relationship
between CD34+ progenitor cells and DPs, CD3+, and CD8+ T
cells, but not between CD34+ progenitor cells and CD4+ T cells.
DPs (Table 3 Part 1, Column 3)
In uninfected controls, increased DPs were correlated with
increased CD4% and absolute CD4+ T cells. In placebo treatment
there was no correlation, but in Prolastin-C treatment, the
relationship between the DPs and CD4% and absolute CD4
counts was corrected to resemble that of uninfected controls
(Table 3 Part 1, column 3, rows 1 and 2).
In uninfected controls, increased DPs were correlated with
decreased CD8%. In HIV-1 infected subjects, Prolastin-C
treatment, but not placebo treatment, corrected the relationship
between the DPs and CD8% to resemble that of uninfected
controls. Prolastin-C treatment also caused decreased DPs to
become correlated with decreased absolute CD8 counts (Table 3
Part 1, column 3, rows 3 and 4).
In uninfected controls, there was no correlation between DPs
and CD3%. However, in placebo treatment, increased DPs were
correlated with increased CD3%. In contrast, in Prolastin-C
treatment, increased DPs were correlated with decreased CD3%
(Table 3 Part 1, column 3, row 6). In uninfected controls,
increased DPs were correlated with increased absolute CD3+ T
cells, but in HIV-1 infected subjects, this correlation was absent
(Table 3 Part 1, column 3, row 7). CD3% is the percent of CD3+ T
cells in the lymphocyte gate. If DPs are not correlated with CD3%
(where the number of total lymphocytes is the denominator),
but are positively correlated with CD3+ T cells, then DPs are
not related to the total number of lymphocytes. In placebo
treatment, where DPs were positively correlated with CD3%, but
not with CD3+ T cells, DPs were negatively related to the number
of lymphocytes, i.e., the more DPs, the fewer lymphocytes. In
Prolastin-C treatment, where DPs were negatively correlated
with CD3%, but not correlated with CD3+ T cells, DPs were
positively related to the number of lymphocytes, i.e., the more
DPs, the more lymphocytes. This interpretation is supported by
the increase in lymphocytes in Prolastin-C treatment, Zemaira
treatment, and Prolastin treatment as compared with placebo
treatment (Table 2, row 12).
In uninfected controls, increased DPs were correlated
with increased CD4/CD8 ratio. In HIV-1 infected subjects,
Prolastin-C treatment, but not placebo treatment, corrected the
relationship between the DPs and CD4/CD8 ratio to resemble
that of uninfected controls (Table 3 Part 1, column 3, row 5).
In uninfected controls and Prolastin-C treatment, there was
no correlation between DPs and CD34+ progenitor cells. In
contrast, in placebo treatment, increased DPs were correlated
with increased CD34+ progenitor cells (Table 3 Part 1, column
3, rows 9).
These combined results suggest that Prolastin-C treatment
altered the relationship between DPs and CD34+ progenitor
cells, between DPs and CD4/CD8 ratio, between DPs and
absolute CD4+ T cells, between DPs and absolute CD8+ T cells,
but not between DPs and absolute CD3+ T cells suggesting
Prolastin-C treatment fostered the development of DPs to
become CD4+ T cells.
sj/β-TRECs (Table 3 Part 2, Column 4)
In uninfected controls and in Prolastin-C treatment, sj/β-TRECs
were not correlated with absolute CD3+, CD4+, or CD8+ T cells.
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TABLE 2 | Effect of α1PI therapy on hematopoietic progenitor cells and T cell phenotypes.
T cell phenotype NCT01731691 NCT01370018
% change Placebo (HIV) % change Prolastin-C (HIV) % change Zemaira (HIV) % change Prolastin (PIzz)
CD4% −5.24 ± 5.10 (38) −0.49 ± 9.00 (23)** 12.81 ± 17.42 (20) 1.85 ± 4.90 (17)
CD4 Abs −5.19 ± 13.16 (38) −6.46 ± 16.46 (23) 65.78 ± 53.00 (21) 14.65 ± 16.10 (15)
CD8% 0.92 ± 4.50 (38) −3.60 ± 3.66 (23)*** −2.86 ± 4.57 (20) −5.97 ± 4.72 (17)
CD8 Abs 1.87 ± 16.97 (38) −8.14 ± 19.49 (23)* 38.91 ± 33.32 (20) 5.67 ± 11.77 (15)
CD4/CD8 Ratio −6.33 ± 6.53 (38) 2.92 ± 9.80 (23)*** 18.31 ± 21.85 (21) 8.70 ± 10.51 (15)
CD3% −1.86 ± 3.46 (38) −2.88 ± 2.86 (23) 2.24 ± 3.18 (20) 1.68 ± 2.81 (17)
CD3 Abs −1.58 ± 15.29 (38) −8.24 ± 18.73 (23) 48.59 ± 40.16 (20) 14.44 ± 14.72 (15)
CD4+CD8+ events 2.15 ± 39.41 (36) 28.05 ± 135.53 (23) N.D. −14.62 ± 73.26 (10)
%CD34+ 158.34 ± 263.23 (36) 20.13 ± 103.46 (14) N.D. 2,187.14 ± 2,770.97 (10)
CD3+HLE+ events 22.61 ± 92.70 (30) 257.63 ± 705.84 (16) N.D. N.D.
sj/β-TRECs 3,115.11 ± 9810.35 (30) 3,456.23 ± 7,463.45 (19) N.D. N.D.
Lymphocytes −2.77 ± 20.4 (30) 18.18 ± 32.92 (23)** 46.60 ± 44.08 (27) 6.75 ± 10.5 (10)
Values depicted represent means and standard deviations of % change from baseline and are color coded with green representing positive changes and red representing negative
changes. The number of observations in placebo-treated (n = 5 subjects), Prolastin-C-treated (n = 3 subjects), Zemaira-treated (n = 3 subjects), and Prolastin-treated subjects (n =
2 subjects) is represented in parenthesis (n). Measurements were not performed in some cases (N.D.). Parameters were not normaly distributed and medians were compared using
Mann-Whitney Rank Sum Test. Askerisks designate a statistically significant difference between placebo and Prolastin-C (*P < 0.05, **P < 0.02, ***P < 0.001). Zemaira-treated subjects
and PIzz clinic patients are presented, but were not compared due to the differences in disease parameters, treatment dose, and lack of HIV-1 infected untreated controls.
Yet, in placebo treatment, increased sj/β-TRECs were correlated
with increased absolute CD3+, CD4+, and CD8+ T cells (Table 3
Part 2, column 4, rows 2, 4, 7). These results suggest that
Prolastin-C treatment corrected the relationship between sj/β-
TRECs and absolute CD3+, CD4+, or CD8+ T cells to resemble
that of uninfected controls.
Active and Inactive α1PI (Table 3, Part 2,
Columns 5 and 6)
In uninfected controls, neither active nor inactive α1PI were
correlated with absolute CD4+ T cells. In placebo and Prolastin-
C treatment, increased active α1PI was correlated with increased
absolute CD4+ T cells and inactive α1PI was correlated with
decreased absolute CD4+ T cells (Table 3, Part 2, columns 5 and
6, rows 1 and 2).
In uninfected controls, increased active α1PI was correlated
with decreased absolute CD8+ T cells and decreased CD3%
whereas increased inactive α1PI was correlated with increased
CD8+ T cells and increased CD3% (Table 3, Part 2, columns
5 and 6, rows 4 and 6). In uninfected controls, there was no
correlation between active and inactive α1PI and CD4/CD8 ratio,
yet in placebo treatment, increased active α1PI was correlated
with decreased CD4/CD8 ratio and in Prolastin-C treatment,
the opposite relationship was found with increased active α1PI
being correlated with increased CD4/CD8 ratio (Table 3, Part 2,
columns 5 and 6, row 5).
With regard to progenitor cells, in uninfected controls,
increased active α1PI was correlated with increased DPs, but
there was no relationship between DPs and inactive α1PI. In
placebo treatment, there was no relationship between DPs and
active or inactive α1PI. However, in Prolastin-C treatment,
increased active α1PI was correlated with increased DPs, and
inactive α1PI was correlated with decreased DPs (Table 3, Part
2, columns 5 and 6, row 8).
In all 3 arms of the study, there was no relationship between
active α1PI and CD34+ progenitor cells, but this was not so
for inactive α1PI. In uninfected controls and placebo treatment,
there was no relationship between inactive α1PI and CD34+
progenitor cells, but in Prolastin-C treatment, increased inactive
α1PI was correlated with increased CD34+ progenitor cells
(Table 3, Part 2, columns 5 and 6, row 9). These combined results
support the interpretation that active α1PI actively increases
CD4/CD8 ratio without increasing DPs, increasing CD34+
progenitor cells, or increasing sj/β-TRECS.
CD3+HLE+ T Cells (Table 3, Parts 1 and 2,
Row 10)
CD3+HLE+ T cells are a principal target for active α1PI.
In uninfected controls, increased CD3+HLE+ T cells were
correlated with increased CD4/CD8 ratio, but this relationship
was not observed in HIV-1 infected subjects with placebo or
Prolastin-C treatment.
In uninfected controls and placebo treatment, CD3+HLE+
T cells were not correlated with CD34+ progenitor cells, yet
in Prolastin-C treatment increased CD3+HLE+ T cells were
correlated with increased CD34+ progenitor cells (Table 3, Part
1, columns 1 and 2, row 10).
In uninfected controls and in placebo treatment, increased
CD3+HLE+ T cells were correlated with increased DPs, but
in Prolastin-C treatment there was no relationship between
CD3+HLE+ T cells and DPs (Table 3, Part 1, column 3, row 10).
There was no relationship between CD3+HLE+ T cells and
sj/β TRECs in any arm (Table 3, Part 2, column 4, row 10).
In uninfected controls, increased CD3+HLE+ T cells were
correlated with increased active α1PI and decreased inactive
α1PI. In placebo treatment, there was no relationship between
CD3+HLE+ T cells and active or inactive α1PI. However,
in Prolastin-C treatment, increased CD3+HLE+ T cells were
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correlated with decreased active α1PI (Table 3, Part 2, columns
5 and 6, row 10).
These results support the interpretation that CD3+HLE+ T
cells interact with active α1PI to regulate DPs and CD4/CD8 ratio
supporting our previous findings that α1PI is rate limiting in
HIV-1 disease for generation of CD4+ T cells and that replacing
α1PI allows HIV-1 infected patients to resemble uninfected
controls (Bristow et al., 2012).
DISCUSSION
Although the number of HIV-1 subjects receiving α1PI therapy in
these two clinical trials is small, the evidence suggests that α1PI
participates in regulating the maturation of DPs to SP CD4+ T
cells thereby elevating CD4/CD8 ratio.
Data from Table 2 show that Prolastin-C treatment
significantly increased CD4/CD8 ratio and total lymphocytes,
and improved CD4%, while significantly decreasing CD8%
and CD8 counts. Data from Table 3 show that Prolastin-C
treatment corrected correlations from abnormal to normal
between CD4/CD8 ratio and CD4 counts as well as between
CD4/CD8 ratio and DPs. These results suggest that Prolastin-C
treatment caused an increase in CD4/CD8 ratio by increasing
absolute CD4+ T cells and by decreasing absolute CD8+ T cells.
Data from Tables 2, 3 show that Prolastin-C treatment altered
relationships between CD34% and DPs, CD34% and CD3%,
CD34% and absolute CD3+ T cells, CD34% and absolute CD8+
T cells, but not between CD34% and CD4% or absolute CD4+
T cells. These results suggest that Prolastin-C treatment caused
an increase in CD4/CD8 ratio and improved CD4% without
TABLE 3 | Effect of α1PI therapy on the relationships between progenitor cells and T cell phenotypes.
1 2 3
N-CD4/CD8
Ratio
P-CD4/CD8
Ratio
Pro-CD4/CD8
Ratio
N-%CD34+ P-%CD34+ Pro-%CD34+ N-CD4+CD8+
DP events
P-CD4+CD8+
DP events
Pro-
CD4+CD8+
DP events
PART 1
1 CD4% 0.847 0.791 0.935 0.375 0.621 0.67
0.000027 2.00E-07 2.00E-07 0.0246 0.0000552 0.000219
36 42 25 36 36 25
2 CD4 Abs 0.724 0.563 0.472 −0.534 −0.401 0.534 0.85
2.00E-07 0.00352 0.00381 0.00036 0.0468 0.000869 2.00E-07
36 25 36 41 25 36 25
3 CD8% −0.961 −0.72 −0.78 −0.36 −0.898 −0.762
2.00E-07 2.00E-07 2.00E-07 0.0313 2.00E-07 2.00E-07
36 72 25 36 36 25
4 CD8 Abs −0.567 −0.796 0.35 −0.379 −0.439
0.000102 2.00E-07 0.0366 0.0149 0.0281
42 25 36 41 25
5 CD4/CD8 0.872 0.726
Ratio 2.00E-07 7.59E-06
36 24
6 CD3% −0.424 0.498 0.433 −0.722
0.0347 0.0116 0.00549 6.66E-06
25 25 40 25
7 CD3 Abs 0.559 −0.444 −0.67 0.506 −0.441 0.415
0.000435 0.00341 0.000219 0.00175 0.00411 0.0122
36 42 25 36 41 36
8 CD4+CD8+ 0.872 0.726 0.66 −0.481
DP events 2.00E-07 7.59E-06 2.30E-06 0.0152
36 24 40 25
9 0.602
%CD34% 4.27E-05
40
10 CD3+HLE+ 0.424 0.437 0.492 0.424
Events 0.0113 0.0365 0.00285 0.00826
35 23 35 38
(Continued)
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TABLE 3 | Continued
4 5 6
N-TRECs P-TRECs Pro-TRECs N-Active a1PI P-Active a1PI Pro-Active
a1PI
N-Inactive
a1PI
P-Inactive
a1PI
Pro-Inactive
a1PI
PART 2
1 CD4% 0.738 −0.669 −0.668
2.00E-07 3.05E-07 0.000167
26 43 26
2 CD4 Abs 0.0206 0.669 0.606 −0.449 −0.579
0.00658 4.64E-07 0.00107 0.00265 0.00195
33 42 26 43 26
3 CD8% 0.644 −0.841 0.589
3.41E-06 2.00E-07 0.00162
42 26 26
4 CD8 Abs 0.227 −0.422 0.671 −0.657 0.385 0.442
0.000263 0.0107 4.01E-07 0.000252 0.0204 0.0237
33 36 42 26 36 26
5 CD4/CD8 −0.347 0.863 0.408 −0.723
Ratio 0.0263 2.00E-07 0.00831 4.29E-06
41 25 41 25
6 CD3% −0.455 0.563 −0.682 0.332 −0.513 0.404
0.00548 0.000116 0.0000956 0.0479 0.000489 0.0407
36 42 26 36 43 26
7 CD3 Abs 0.21 0.672 −0.537
6.26E-04 3.11E-07 0.00484
33 42 26
8 CD4+CD8+ 0.326 0.768 −0.607
DP events 0.0526 2.00E-07 0.00134
36 25 25
9 0.554
%CD34% 0.00514
24
10 CD3+HLE+ 0.449 −0.476 −0.355
events 0.00709 0.0163 0.0365
35 25 35
Subject designations (top row) represent uninfected, untreated (“N” violet, n = 4 subjects), placebo-treated (“P” light orange, n = 5 subjects), and Prolastin-C-treated (“Pro” blue, n =
3 subjects). Boxes containing correlations are color-coded with red representing negative correlations, green representing positive correlations, white representing no correlation, and
gray representing irrelevant correlations. Light green represent correlations that approached, but did not reach significance. The values depicted within each box represent correlation
coefficients (r, top row), significance (P, middle row), and number of observations (n, bottom row).
increasing CD34%, but by modifying the relationship between
CD34% as well as DPs with absolute CD8+ T cells.
Data from Table 3 show that Prolastin-C treatment corrected
to normal relationships between DPs and CD4/CD8 ratio,
between DPs and CD4%, between DPs and absolute CD4+ T
cells, between DPs and CD8%, between DPs and CD34%, but
not between DPs and CD3% or absolute CD3+ T cells. These
results suggest that Prolastin-C treatment caused an increase in
CD4/CD8 ratio and improved CD4%without increasingDPs, but
by modifying the relationship between DPs and absolute CD4+ T
cells and absolute CD8+ T cells.
Data from Table 3 show that Prolastin-C treatment corrected
to normal relationships between TRECs and absolute CD3+ T
cells, TRECs and absolute CD4+ T cells, and TRECs and absolute
CD8+ T cells. These results suggest that Prolastin-C treatment
caused an increase in CD4/CD8 ratio and improved CD4%
without increasing TRECs, but by modifying the relationship
between TRECs and absolute CD4+ T cells, CD8+ T cells and
CD3+ T cells.
Data from Table 3 show that Prolastin-C corrected to normal
relationships between active α1PI and absolute CD8+ T cells,
between active α1PI and CD3%, between active α1PI and DPs,
but not between active α1PI and absolute CD4+ T cells or
CD34%. These results suggest that Prolastin-C treatment caused
an increase in CD4/CD8 ratio and improved CD4% at a step
between CD34% and CD4+ T cells.
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Considering that during maturation, CD3 is expressed
simultaneously with the TcR, the lack of a significant sj/β-
TREC change from baseline in Prolastin-C-treated subjects
is reasonable since there was also not a significant absolute
CD3+ T cell change from baseline. In placebo-treated HIV-
1 infected subjects, increased sj/β-TRECs were correlated with
increased absolute CD3+, CD4+, and CD8+ T cells, but this
correlation was not observed for uninfected, untreated controls.
Prolastin-C therapy corrected the realtionship between sj/β-
TRECs and absolute CD3+, CD4+, and CD8+ T cells to
correspond to uninfected controls (no correlation) supporting
evidence that α1PI, without significantly increasing sj/β-TRECs,
DPs, CD34%, or absolute CD3+, CD4+, or CD8+ T cells is
integral to the maturation of CD4+ T cells, clearly from DPs
(Bristow et al., 2012).
The difference between Zemaira and Prolastin-C treatment
to elevate CD4 counts vs. decrease CD8 counts was attributed
to the difference in subject populations since both drug
lots were found to have the same activity during FDA
approval. The Zemaira trial enrolled homosexual, HIV-1 infected
individuals that were compared to uninfected, α1PI genetically
deficient individuals with no evidence of systemic inflammation,
whereas the Prolastin-C trial enrolled, almost entirely, IV
drug users, all of whom exhibited consistent or sporadically
elevated CRP, a marker of inflammation. Inflammation is
known to elevate cytokines and enzymes that could influence
thymopoiesis, and evidence has established that inflammation
is inversely correlated with DPs (Bristow et al., 1998; Ferrando-
Martinez et al., 2009). That α1PI therapy increased CD4/CD8
ratio by either increasing the number of absolute CD4+ T
cells or decreasing the number of absolute CD8+ T cells,
depending on patient population, suggests, unsurprisingly, that
there are additional factors that determine the phenotype of
SP cells.
Evidence published in the early 1980’s demonstrated that four
T cell alloantigens in mice encoded by genes on chromosome
12 are expressed in discrete T cell phenotypes, suggesting these
genes participate in thymopoiesis (Owen and Riblet, 1984).
The four mouse genes located near the immunoglobulin heavy
chain gene are distinctly expressed on what were termed,
at that time, Tind (T helper, CD4+, OKT4+, Lyt-1+), Tsu
(T suppressor, CD8+, Lyt-2+3+), Tthy (thymocytes, DP, Lyt-
1+2+3+), and Tpre (Tthy precursors) (Owen et al., 1982; Owen,
1983). It was widely and enthusiastically anticipated that like
immunoglobulin gene rearrangement, the four T cell alloantigen
genes rearranged with the immunoglobulin heavy chain gene
to form a T cell antigen receptor, the existence and structure
of which was hotly disputed to be an immunoglobulin-like
protein named IgT (Marchalonis, 1975; Janeway et al., 1976;
Marchalonis and Cone, 2002). However, within a year, the
mouse T cell antigen receptor genes were cloned, sequenced,
and found to be encoded on chromosomes 6, 13, and 14,
not chromosome 12 (Hedrick et al., 1984; Yanagi et al., 1984;
Brenner et al., 1986). This surprising revelation shattered the
hypothesis that the four mouse T cell alloantigens were part
of the T cell antigen receptor and regrettably provided no
information as to what is encoded on chromosome 12 that
discriminates T cell functional phenotypes. Ultimately, it was
shown that the four monoclonal antibodies that discriminated
the four mouse T cell alloantigens all bind specifically to
human α1PI, a protein encoded on mouse chromosome 12 and
on human chromosome 14 near the immunoglobulin heavy
chain gene (Dembic et al., 1985; Bristow and Flood, 1993).
Whereas, there is one human gene that expresses α1PI, there
is a cluster of 6 expressed mouse α1PI genes (UnitproKB–
P07758). These combined data are a compelling indication that
mouse α1PI isoforms and human α1PI regulate thymopoiesis.
Further, by inactivating human α1PI, 3F5 HIV-1 antibody
has been shown to inhibit the generation of new CD4+
T cells.
As a natural host for HIV-1, chimpanzees (Pan troglodytes)
can be infected with HIV-1, but they neither develop
AIDS, nor permanently lose their CD4+ T cells. A primary
reason for the relative resistance of these primates to
develop AIDS is that monoclonal antibody 3F5 does not
bind to chimpanzee α1PI due to a single amino acid
difference caused by one nucleotide difference in human
α1PI that lies within the 3F5-binding region of the protein
(Bristow et al., 2012).
A strategy is proposed in which HIV-1 vaccination
includes induction of an antibody that blocks 3F5 activity,
thereby preventing the autoimmune influence that
produces acquired α1PI deficiency and, as a consequence,
inhibits CD4+ T cell maturation. Such a vaccine would
attempt to prevent AIDS in addition to current attempts
to prevent HIV-1 infection, a situation which might
allow humans to simulate the illness experienced by
chimpanzees infected with HIV-1 and to survive infection
relatively unscathed.
Treating HIV-1 patients for the purpose of elevating CD4+ T
cells using mutated α1PI might be feasible, potentially using the
chimpanzee sequence, yet there is a risk that mutated α1PI might
also stimulate antibodies against the mutated sequence. A less
risky treatment is to develop small molecules that target HLE-CS
and produce the same cellular response as α1PI.
Our group has identified a panel of orally-available small
molecules that bind to HLE-CS and induce cellular locomotion.
In several pre-clinical mouse studies, our lead molecule has been
demonstrated to increase the number of CD4+ T cells with no
untoward side effects in two mice strains with varying disease
states (unpublished results pending completion of pre-clinical
studies). The development of small molecules in these studies
are encouraging that, for the first time, treatment of secondary
immunodeficiency may be possible.
FOOTNOTE
Some data from an earlier clinical trial presented herein
were previously published in an open-access eBook chapter,
“α1Antitrypsin therapy increases CD4+ lymphocytes to normal
values in HIV-1 patients.” In: M. Alfano, editors. Soluble factors
mediating innate immune responses to HIV infection, Bentham
Science Publishers, and are exhibited here in an alternative
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format for comparison to data from a second, more extensively
investigated, previously unpublished clinical trial.
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